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Objective: Dysphagia remains a side effect influencing
the quality of life of patients with head and neck cancer
(HNC) after radiotherapy. We evaluated the relationship
between planned dose involvement and acute and late
dysphagia in patients with HNC treated with intensity-
modulated radiation therapy (IMRT), after a recontouring
of constrictor muscles (PCs) and the cricopharyngeal
muscle (CM).
Methods: Between December 2011 and December 2013,
56 patients with histologically proven HNC were treated
with IMRT or volumetric-modulated arc therapy. The PCs
and CM were recontoured. Correlations between acute and
late toxicity and dosimetric parameters were evaluated. End
points were analysed using univariate logistic regression.
Results: An increasing risk to develop acute dysphagia
was observed when constraints to the middle PCs were
not respected [mean dose (Dmean) $50Gy, maximum
dose (Dmax) .60Gy, V50 .70% with a p50.05]. The
superior PC was not correlated with acute toxicity but only
with late dysphagia. The inferior PC was not correlated
with dysphagia; for the CM only, Dmax .60Gy was co-
rrelated with acute dysphagia $ grade 2.
Conclusion: According to our analysis, the superior PC
has a major role, being correlated with dysphagia at 3 and
6 months after treatments; the middle PC maintains this
correlation only at 3 months from the beginning of
radiotherapy, but it does not have influence on late
dysphagia. The inferior PC and CM have a minimum
impact on swallowing symptoms.
Advances in knowledge: We used recent guidelines to
define dose constraints of the PCs and CM. Two results
emerge in the present analysis: the superior PC influences
late dysphagia, while the middle PC influences acute
dysphagia.
In the past decade, substantial progress has been made in
the treatment of head and neck cancer (HNC). Several
reports show that radiotherapy (RT) with concomitant
chemotherapy or altered fractionation schedules improve
tumour control and survival rate.1,2
However, xerostomia and dysphagia often remain relevant
side effects for patients with HNC, compromising their
quality of life (QoL), as a consequence of radiation damage
to the parotid glands and to the organ at risk (OAR) in-
volved in the swallowing process (SWOARs).3
Intensity-modulated radiation therapy (IMRT) and rota-
tional intensity-modulated techniques, including volumetric-
modulated arc therapy (VMAT), allow for a better dose
conformation to target structures while reducing the dose.4–8
In comparison with three-dimensional-conformal radi-
ation therapy, several studies have shown that IMRT in
HNC treatment reduces overall adverse effects such as
xerostomia and dysphagia and thus improves QoL, even
when chemotherapy is added.9–13
Regarding tolerance of the parotid glands, several studies
have suggested signiﬁcant recovery when the mean dose is
inferior to 26Gy. Open questions remain for SWOARs,
especially with reference to the delineation modalities of the
involved structures to the volumes or the dose constraints to
be applied.14–18 More authors hypothesized that sparing
a portion of the constrictor muscles (PCs), not involved by
tumour and not at risk of subclinical disease, might reduce
dysphagia.19–21 These studies obtained different results, maybe,
owing to a number of methodological issues and to the ambig-
uous contouring of the PCs. For this purpose, Christianen
et al22 recently deﬁned guidelines for SWOARs contouring.
Based on these ﬁndings, the aim of this retrospective analysis is
to evaluate potential relationships between planned dose–volume
parameters and observed incidence of acute and late dysphagia
in patients with HNC treated with IMRT or VMAT, after a
recontouring of the PCs according to these recently published
guidelines.
METHOD AND MATERIALS
Patients
Between December 2011 and December 2013, 56 patients (43
males and 13 females), with a median age of 64 years (range,
24–86 years) and with histologically proven HNC, received radi-
ation treatment with IMRTor VMAT in Sacro Cuore-Don Calabria
Hospital, Negrar-Verona, Italy. .10% of the patients had non-
squamous histology (carcinoma undifferentiated, lymphoepi-
thelial, sarcomatoid, mucoepidermoid). Patients’ characteristics are
shown in Table 1.
Each patient underwent a pre-treatment evaluation that in-
cluded a complete history and physical examination, CT and/or
MRI scans and/or ﬂuorine-18 ﬂudeoxyglucose–positron emis-
sion tomography (18F-FDG-PET) of the head and neck region,
and direct ﬂexible ﬁberoptic endoscopic examination.
Planning
Immobilization of each patient for simulation and during
treatment was achieved with a thermoplastic head and shoulder
mask (Civco, Orange City, IA). A treatment-planning CT with
3-mm slice thickness and intravenous contrast was acquired in
the treatment position and matched with 18F-FDG-PET or MRI
in the treatment position to better deﬁne the biological target
volume and/or clinical target volume (CTV) and OARs.
According to the Radiation Therapy Oncology Group (RTOG)
guidelines,23 the following OARs were contoured for the pre-
treatment planning: the spinal cord, brain stem, ipsilateral and
contralateral parotid glands, oral cavity and larynx (for non-
laryngeal cancers). Whenever close to the planning target volume
(PTV), the eyes, optic nerves, and optic chiasm were delineated.
In radical setting, gross tumour volume (GTV), high-risk sub-
clinical disease (CTV1) and low-risk subclinical disease (CTV2)
were deﬁned on CT scan after simulation procedure. PTV1,
PTV2 and PTV3 were generated with an isotropic expansion of
5mm from CTV1, CTV2 and CTV3, respectively. These vol-
umes were irradiated to a total dose of 70Gy (33–35 fractions),
59.94–63.00Gy (33–35 fractions) and 54.45–58.1Gy (33–35
fractions), respectively, with daily fractions of 2.12/2.00Gy,
1.80/1.81Gy and 1.65/1.66Gy with simultaneous-integrated boost.
In the post-operative setting, two volumes of interest were
identiﬁed: CTV1 including the tumour bed (primary and in-
volved nodes) and CTV2 including elective lymphatic areas.
PTV1 and PTV2 were generated with an isotropic expansion of
Table 1. Patient baseline characteristics and demographics
(n 5 56)
Factors Description
Gender
Male 77% (n5 43)
Female 23% (n5 13)
Age
Age (years) Median, 64; range 24–86
Smoker
Yes 77% (n5 43)
No 23% (n5 13)
Diabetic
Yes 5% (n5 3)
No 95% (n5 53)
Primary site
Rinopharynx 9% (n5 5)
Oropharynx 30% (n5 17)
Oral cavity 18% (n5 10)
Larinx sovraglottic 9% (n5 5)
Larinx glottic 30% (n5 17)
Salivary glands 4% (n5 2)
Histology
Epidemoidal 88% (n5 49)
Others 13% (n5 7)
Grading
Grade 1 27% (n5 15)
Grade 2 46% (n5 26)
Grade 3 27% (n5 15)
Stage
I 20% (n5 11)
II 13% (n5 7)
III 18% (n5 10)
IVA 46% (n5 26)
IVB 4% (n5 2)
Chemotherapy
Cisplatino weekly 20% (n5 11)
Cisplatino 3-weekly 32% (n5 18)
Induction 2% (n5 1)
None 46% (n5 26)
Radiotherapy
Radical 71% (n5 40)
Adjuvant 29% (n5 16)
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5mm from CTV1 and CTV2, respectively. These volumes were
irradiated to a total dose of 60Gy in 30 fractions and 54Gy in
30 fractions, respectively, with daily fractions of 2Gy and 1.8 Gy,
respectively.
The dose was prescribed to cover 95% of the PTV. Target dose
homogeneity was obtained by maintaining V107% dose prescription
(Dp) ,3% and a maximum dose (Dmax) ,110% Dp.
Planning objectives required PTV coverage of 95–107%. Con-
cerning OARs, they were set as follows: the spinal cord: Dmax
0.1 cc ,46Gy; brain stem: Dmax 0.1 cc ,54Gy; parotid glands:
V30 ,45%; mean dose (Dmean) ,26Gy; larynx, V40 ,50%;
and oral cavity (not involved), V40,50%. All dose distributions
were computed with the anisotropic analytical algorithm v. 10.0.28
implemented in the Eclipse™ (Varian, Palo Alto, CA) treatment
planning system with a calculation grid resolution of 2.5mm.
Figure 1. (a–d) Definition of the constrictor and cricopharyngeal muscles in axial CT slice.
Table 2. Anatomic borders of constrictors and cricopharyngeal muscles
Muscle Cranial Caudal Anterior Posterior Lateral Medial
Superior PCM
Caudal tip of the
pterygoid plates
(hamulus)
Lower edge of C2
Hamulus of
pterygoid plate;
mandibula; base of
tongue; pharyngeal
lumen
Prevertebral
muscle
Medial pterygoid
muscle
Pharyngeal
lumen
Middle PCM Upper edge of C3
Lower edge of
hyoid bone
Base of tongue;
hyoid bone
Prevertebral
muscle
Greater horn of
hyoid bone
Pharyngeal
lumen
Inferior PCM
First slice caudal to
the lower edge of
hyoid bone
Lower edge of the
arythenoid
cartilages
Soft tissue of
supraglottic/glottic
larynx
Prevertebral
muscle
Superior horn of
thyroid cartilage
Pharyngeal
lumen
Cricopharyngeal
muscle
First slice caudal to
the arytenoid
cartilages
Lower edge of the
cricoid cartilages
Posterior edge of
cricoid cartilage
Prevertebral
muscle
Thyroid cartilage,
fatty tissue, thyroid
gland
C2, second cervical vertebra; C3, third cervical vertebra; PCM, pharyngeal constrictor muscle.
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All plans were performed with 9-ﬁeld sliding window IMRT or
4-arc VMAT (Rapid Arc; Varian Medical System, Palo Alto, CA)
and nominal energy of 6MV.
Treatment procedure
Before each daily fraction, the patients were submitted to image-
guided radiotherapy (IGRT) procedure by means of a daily tube
potential–cone beam CT (CBCT) to check and correct in real-
time set-up errors and to follow anatomical changes of the
treated region.
CBCT low-dose head model (80 kVp, 0.4mAs) was used to
generate images; clockwise and anticlockwise 180° gantry rota-
tions were used alternatively to reduce dose to patients.24
All corrections carried out after matching between CBCT and
planning CT were recorded and collected.
Chemotherapy
Cisplatinum 100mgmq21 was added every 21 days during RT
for patients with performance status (PS) Eastern Co-
operative Oncology Group (ECOG)5 0–1, age less than 70
years, disease T/N1 or T3–T4/N0; cisplatinum 30mgmq21
was added weekly if PS5 2, age less than 70 years, disease T/
N1 or T3–T4/N0; induction TCF (docetaxel, cisplatin, 5-
ﬂoruracile) if PS5 0, age less than 65 years, disease T/N3; and
no chemotherapy if PS ECOG .2, disease T1–T2/N0, age
over 70 years.25
Toxicity evaluation and follow-up
At baseline, no cases of dysphagia and xerostomia were recorded.
Toxicity was evaluated weekly during radiation treatment, and pe-
riodically after the end of the treatment: 1 month after RT clinical
evaluation, then regular visits every 3 months for the ﬁrst 2 years.
Toxicities occurring within 3 months from the beginning of
radiotherapy were deﬁned as acute, and those occurring after
3 months as late toxicity. Patients were assessed for toxicities
by the European Organization for Research and Treatment for
Cancer/RTOG radiation morbidity scoring criteria. Clinical data
were collected and evaluated for statistical evaluation.
Re-contouring
The compliance to radiation treatment was 100%; no patient
interrupted or discontinued the planned IMRTor VMAT schedule;
and, for the end point of the study, all clinical and dosimetrical
data were retrospectively evaluated.
On planning CT scan, the PCs were retrospectively contoured
according to Christianen et al22 guidelines by a single observer
and subsequently reviewed by another radiation oncologist as
shown in Figure 1. The PCs and the cricopharyngeal muscle
(CM) were indicated as shown in Table 2.
Statistical analysis
Descriptive statistics were used to analyse the data. End points
were analysed using univariate logistic regression and contin-
gence tables with Fisher’s exact test for the association between
acute/late dysphagia, dose–volume and clinical parameters.
Dosimetric parameters for each PC and CM were related to
acute and late toxicities (during RT, at 3, 6 and 12 months from
RT). We evaluated a sort of “constraints-escalation” from V30
increasing every 5 Gy until maximum dose was reported in the
dose–volume histogram (DVH) of each structure (Figure 2).
The dosimetric parameters for ipsilateral and contralateral pa-
rotid glands were Dmean .26Gy and V30 .50%.
p# 0.05 was considered signiﬁcant. Data were analysed using
R-software (Varian, Palo Alto, CA).
Locoregional control and overall survival were estimated using the
Kaplan–Meier method. Time to recurrence and overall survival
were calculated from the date of diagnosis to the date of relapse
and the date of death or last follow-up, respectively.
RESULTS
Acute and late toxicity
During RT, acute dysphagia and xerostomia were registered as follows:
Grade (G) 0–1 in 10 patients (18%), G2 in 36 patients (64%), G3 in
10 patients (18%); and G0–1 in 25 patients (45%), G2 in 30 patients
(54%), G3 in 1 patient (1%), respectively. No case of G4 toxicity was
registered.
At 3 months from the end of RT, toxicity was reported as fol-
lows: G0–1 dysphagia in 33 patients (59%), G2 in 18 patients
(32%), G3 in 5 patients (9%); G0–1 xerostomia in 30 patients
(54%) and G2 in 26 patients (46%).
Figure 2. Definition of the constrictor and cricopharyngeal
muscles in sagittal projection. A, anterior; P, posterior; S, superior.
BJR R Mazzola et al
4 of 10 birpublications.org/bjr Br J Radiol;87:20140543
Table 3. Dosimetric factors for constrictors: univariate logistic regression analysis
Structures Dysphagia Constraints
Volume (cm3) and
median (range)
Univariate analysis
OR p-value 95% CI
SPC
Acute
3 months
6 months
Dmax 60
Dmean 50
V50
V55
V65
Dmax 60
Dmean 50
V50
V55
V65
Dmax 60
Dmean 50
V50
V55
V65
11.3 (10.8–12.4)
3.18
1.875
1.55
2.16
1.05
12.52
9.6
6.78
10
2.25
1.86
9.33
NA
NA
4.37
0.197
0.450
0.702
0.449
1.00
0.01
0.006
0.007
0.001
0.304
0.65
0.03
0.027
0.01
0.117
0.38–11.6
0.41–8.51
0.34–7.02
0.46–10.16
0.18–5.97
1.48–105.58
1.89–48.6
1.64–28.04
2.38–12.01
0.60–8.42
0.33–10.41
0.99–87.38
NA
NA
0.74–25.8
MPC
Acute
3 months
6 months
Dmax 60
Dmean 50
V50
V55
V65
Dmax 60
Dmean 50
V50
V55
V65
Dmax 60
Dmean 50
V50
V55
V65
2.02 (1.70–2.64)
3.18
8.5
13.25
9.1
NA
12.52
7.52
4.2
2.71
2.36
1.86
3.26
4.77
5.75
0.51
0.197
0.01
0.008
0.05
0.08
0.009
0.013
0.039
0.144
0.204
0.65
0.39
0.204
0.189
1
0.68–14.88
1.50–47.96
1.48–116.26
1.03–80.08
NA
1.48–105.58
1.48–38.07
1.13–15.49
0.81–90
0.66–8.35
0.33–10.41
0.35–30.7
0.51–44.32
0.61–53.42
0.054–4.89
IPC
Acute
3 months
6 months
Dmax 60
Dmean 50
V40
V50
V55
V65
Dmax 60
Dmean 50
V40
V50
V55
V65
Dmax 60
Dmean 50
V40
V50
V55
V65
5.4 (4.2–5.8)
2.06
1.42
2.53
1.09
1.09
2.30
1.14
0.81
0.86
0.58
0.58
0.4
1.07
1.44
2.41
0.86
0.86
NA
0.43
0.711
0.24
1.00
1.00
0.44
1
0.772
1
0.39
0.39
0.23
1
1
0.65
1
1
NA
0.45–9.41
0.31–6.40
0.55–11.69
0.24–4.89
0.24–4.89
0.42–12.67
0.34–3.83
0.25–2.59
0.25–2.97
0.18–1.87
0.18–1.87
0.11–1.40
0.17–6.54
0.23–8.73
0.25–22.66
0.15–4.80
0.15–4.80
NA
Crico
Acute
3 months
Dmax 60
Dmean 50
V40
V50
V55
V65
Dmax 60
Dmean 50
V40
V50
1.4 (1.2–1.8)
NA
1.66
3.18
2.75
3.73
NA
0.43
0.66
1.13
0.59
0.04
0.7
0.197
0.277
0.411
0.176
0.35
0.56
1
0.55
NA
0.35–7.8
0.68–14.88
0.50–15.07
0.42–33.07
NA
0.11–1.63
0.21–2.11
0.31–4.02
0.18–1.92
(Continued)
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At 6 months from RT, G0–1 dysphagia was recorded in 43 patients
(77%) and G2 in 13 patients (23%), while G0–1 xerostomia was
registered in 39 patients (70%) and G2 in 17 patients (30%),
respectively. No G3 toxicity occurred.
At 12 months from RT, toxicity was: G0-1 dysphagia in
44 patients (91%), G2 in 4 patients (9%); G0–1 xerostomia in
41 patients (85%), G2 in 7 patients (15%). No G3 toxicity occurred.
In ﬁve patients with oropharynx disease and in two patients with
supraglottic disease feeding tubes [percutaneous endoscopy
gastrostomy (PEG)] were placed. In detail, in two patients they
were placed prophylactically by surgeon, and in the other case
for G3 acute dysphagia, only in two patients was the treatment
stopped for 7 days. Five patients maintained PEG for 6 months
after the end of treatment, and in two patients, PEG was re-
moved after 3 months for symptom resolution.
Clinical outcomes
At a median follow-up of 24 months (range, 10–36 months),
2 years actuarial overall survival (OS) was 100% and 2 years
actuarial local control was 96.3%. 3 years OS was 88.9% (we
registered one death), while 3 years local control was 57%; in
detail, we registered four local failures (all patients with locally
advanced disease treated without concomitant chemotherapy).
All patients received their chemotherapy as planned.
Dosimetric parameters for superior
constrictor muscle
For acute dysphagia $G2, no dosimetric parameters showed a
statistical correlation.
At 3 months from RT, Dmean$ 50 Gy, Dmax$ 60 Gy, V50 and
V55 $70% increased the risk of toxicity (p, 0.01, p, 0.05,
p, 0.01 and p, 0.01, respectively). No statistical correlation
was found with the other constraints.
For late dysphagia $G2 (at 6 months from RT), the dosimetric
parameters that showed major correlations were V50, V55 and
V60 $70% with an increasing risk of toxicity from three to
nine times (p, 0.05). For late dysphagia $G2 (at 12 months
from RT), no dosimetric parameters showed a statistical
correlation.
Dosimetric parameters for middle constrictor muscle
For acute dysphagia $G2, Dmean$ 50 Gy and 55 Gy, and
V50 $70% increased the risk of toxicity (p, 0.05, p, 0.05
and p, 0.01, respectively). No statistical correlation was found
with other constraints.
At 3 months from RT, Dmean$ 50 Gy, Dmax$ 60 Gy and
V50 $70% increased the risk of toxicity (p, 0.01, p, 0.05 and
p, 0.01, respectively). No statistical correlation was found with
other constraints.
For late dysphagia $G2 (at 6 and 12 months from RT), no
dosimetric parameters showed a statistical correlation.
Dosimetric parameters for inferior
constrictor muscle
No dosimetric parameter showed a statistical correlation for
acute/late dysphagia $G2 (during treatment and at 3, 6 and
12 months from RT).
Dosimetric parameters for cricopharyngeal muscle
During treatment, only Dmax. 60Gy showed a correlation with
dysphagia $G2 (p, 0.05), while no dosimetric parameter was
related to acute/late toxicity.
Dosimetric parameters for ipsilateral parotid gland
Dmean. 26Gy and V30 .50% are statistically related with acute
xerostomia $G2 (p, 0.0001; odds ratio: 1.06; 95% CI:
1.03–1.10) with an increasing risk of 1.06 times for every
Gray over 26 Gy and xerostomia at 6 and 12 months from
RT [p, 0.05; odds ratio: 1.04; 95% conﬁdence interval (CI):
1.01–1.07], with an increasing risk of 1.04 times for every Gray
over 26 Gy, at 6 and 12 months.
Dosimetric parameters for contralateral
parotid gland
Dmean. 26Gy and V30 .50% are statistically related with
acute xerostomia $G2 (p, 0.001; odds ratio: 1.21; 95% CI:
Table 3. (Continued)
Structures Dysphagia Constraints
Volume (cm3) and
median (range)
Univariate analysis
OR p-value 95% CI
6 months
V55
V65
Dmax 60
Dmean 50
V40
V50
V55
V65
0.43
0.46
NA
0.95
0.86
1.15
0.37
NA
0.35
0.33
0.159
1
1
1
0.64
0.314
0.11–1.63
0.1–1.95
NA
0.17–5.26
0.14–5.33
0.2–6.35
0.039–3.49
NA
CI, confidence interval; Crico, cricopharyngeal muscle; Dmax, maximum dose; Dmean, mean dose; IPC, interior constrictor muscle; MPC, middle
constrictor muscle; NA, OR not estimable; OR, odds ratio; SPC, superior constrictor muscle; V40, volume structure receiving $40Gy; V50, volume
structure receiving $50Gy; V55, volume structure receiving $55Gy; V60, volume structure receiving $60Gy.
p-value estimated with Fisher’s exact test.
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1.10–1.33) with an increasing risk of 1.2 times for every Gray over
26Gy and xerostomia at 6 and 12 months from RT (p, 0.05;
odds ratio: 1.10; 95% CI: 1.03–1.17), with an increasing risk of 1.1
times for every Gray over 26Gy, at 6 and 12 months.
All dosimetric data of PCs are shown in Table 3.
Correlations between clinical factors and dysphagia
Univariate logistic regression analysis for clinical parameters
showed a signiﬁcant correlation with oropharynx primary site
(p, 0.05) and acute/late dysphagia. No correlations with sex,
smoke of cigarette, diabetes, stage of disease and chemotherapy,
when added, were shown. Moreover, late xerostomia $G2 is
statistically related with dysphagia $G2 (p, 0.05).
DISCUSSION
IMRT and VMAT achieved an excellent dose distribution, es-
pecially in a concave-shaped target volume and for patients with
HNC; they have shown a reduction in RT toxicity.4–8 For this
reason, in the past few years, the evaluation of OARs, in terms of
variation in volume, geometry or contouring methods, was
analysed by several authors to improve therapeutic ratio re-
ducing the risk of toxic effects.17–21,26–28
Swallowing dysfunction after radiotherapy is correlated with
compromised QoL and can lead to life-threatening complica-
tions. Limiting the radiation dose to the crucial SWOARs is
expected to decrease the incidence and severity of radiation-
induced dysphagia.
Based on the ﬁndings of video ﬂuoroscopy, Eisbruch et al20 were
the ﬁrst to identify the dysfunction of PCs and other structures
crucial for long-term dysphagia and aspiration in HNC after
concurrent chemoradiotherapy. No distinction was made in this
study among the various levels of the PCs, so they were outlined
as a single structure for dose assessment purpose. In their
analysis, mean dose to the PCs and larynx .50Gy both corre-
lated signiﬁcantly with the occurrence of late dysphagia and
aspiration, respectively.
Levendag et al21 assessed the relationship between RT dose re-
ceived by the muscular components of the PCs and dysphagia
related to QoL in oropharyngeal cancer. For late dysphagia,$G3
signiﬁcant relationships were found between a Dmean. 50 Gy
for superior and middle PC. The probability of PC disorders
increased signiﬁcantly with dose (619% per 10Gy after 55Gy)
for the superior and middle PCs. In the multivariate analysis,
concomitant chemotherapy was not an inﬂuencing factor.
Caglar et al29 evaluated early dysfunction of SWOARs after
IMRT with or without chemotherapy and attempted to de-
termine the clinical and/or dosimetric factors correlating with
swallowing toxicity. They did not ﬁnd any correlation with the
superior PC dose and early dysphagia, whereas the Dmean$ 50Gy
to the larynx and inferior PC was a signiﬁcant predictor for
aspiration.
Similar to these studies, in our series a possible correlation
of dose to middle PC was noted, with an increasing risk to
develop acute toxicity when constraints are not respected.
Superior PC was not correlated with acute toxicity, but sta-
tistical analysis showed a probable pathogenetic role in late
dysphagia.
Dirix et al30 wanted to establish a relationship between late
dysphagia and RT doses to the SWOARs correlating clinical
parameters such as the impact of tumour site, tumour stage and
pre-treatment swallowing problem. The SWOARs identiﬁed
were PCs, base of the tongue, supraglottic larynx, glottic larynx
and CM. At univariate analysis, a mean dose $50Gy to middle
PC, inferior PC and to supraglottic larynx signiﬁcantly corre-
lated with late dysphagia.
Only one study31 did not ﬁnd any relationship between dose to
the PCs and late dysphagia.
In the study of Mortensen et al,32 65 patients were examined for
PC disorders with modiﬁed barium swallow (MBS). Similar to
our analysis, PCs were delineated as described by Christianen
et al22, and the DVHs of OARs were analysed. Late dysphagia
correlated with the dose to superior and middle PCs (all
p, 0.04). Dmean to the superior PC ,60 Gy correlated with
low risk of aspiration (,30%) and Dmean to the middle
PC ,60Gy correlated with low risk of high MBS score (,30%).
With regard to our results, several considerations could be
performed. In our series, only ten patients developed G3 acute
dysphagia; at 3 months, ﬁve patients developed G3 dysphagia;
and no case of G3 developed dysphagia at 6 months and 12 months.
We decided to homogenize the toxicity in two classes: G0–1 and
$G2, because no signiﬁcantly statistical result was found for G3
toxicity owing to limited cases.
The inferior PC seems not to be correlated with acute or late
dysphagia, for CM only Dmax. 60Gy is correlated with dys-
phagia during RT $G2. Thus, these structures seem to have a
minimum or not impact for swallowing symptoms. On the
contrary, the superior PC seems to have a major role, being
correlated with dysphagia at 3 and 6 months, while middle PC
maintains this correlation only until 3 months from the begin-
ning of RT, and it seems to not have an inﬂuence on late
dysphagia.
The studies available in literature retrieved different results, this
may be owing to a number of methodological issues and the
unambiguous contouring of swallowing structures. With these
uncertainties, it is necessary to standardize these aspects.
In our analysis, using Christianen guidelines to deﬁne PMs and
CM, interesting results for the readers have been reported. The
ﬁrst ﬁnding was that when changing limits of the structures, in
particular of the superior PC, using Christianen deﬁnition,
results are similar to data reported in literature. It means that,
maybe, the volume of the structures did not inﬂuence the
constraints. Another interesting ﬁnding was that the middle
pharyngeal constrictor was related to acute dysphagia, while
the superior pharyngeal constrictor inﬂuenced late dysphagia.
A clear deﬁnition of different structures (and an evaluation of
Full paper: Constrictor muscles definition in head and neck IMRT BJR
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their involvement) could inﬂuence differently acute and late
settings of toxicities.
Future evaluations on the impact of volumes of the critical
structures on coverage and homogeneity of the target are needed.
Starting from this background, we decided to propose and apply
in our department the following constraints for PCs, with a
minor priority with respect to PTV coverage: Dmean# 50Gy,
Dmax# 60, V50 ,70% for middle PC; Dmax# 60Gy, V50 ,70%
for superior PC; Dmax# 60Gy for CM.
Regarding to the dose constraints for parotid glands, our analysis
showed that for ipsi and contralateral parotid glands,
Dmean. 26Gy and V30 .50% are statistically related with acute
and late xerostomia $G2, as reported in literature.33 Moreover
the presence of late xerostomia .G2 is statistically related with
dysphagia $G2 (p, 0.05), showing a close relationship between
salivation and swallowing.
We are conscious that the results of the present study are
inﬂuenced by several limitations. The main limitation regards
the lack of methodology due to the retrospective approach.
For this reason we will use the previously described con-
straints in clinical practice in a prospective way, before vali-
dating their value deﬁnitively. The second limitation regards
the population of study: ﬁrst of all the sample size is small, and
moreover, we analysed in the same group radical and adjuvant
treated patients, with different primary disease sites in head and
neck region and subsequently with different treated volume.
However, these limitations are quite similar to the other reports
previously published as shown in Table 4,29–32 where several
results seems to be close to ours and furthermore, despite the
declared limitations, the results about parotid glands conﬁrmed
the literature data.
Another criticism of the present analysis is that it was focused
only to PCs and CM, with a lack of evaluation of other
SWOARs, including base of tongue, supraglottic larynx, upper
oesophagus. The rationale of this choice depended on the mixed
population of study composed by several cases of oropharynx
and larynx diseases. In our opinion, in these cases, due to being
involved with the diseases, it was not possible to consider them as
SWOARs and for this reason we restricted the analysis only to
role of PCs in swallowing disorders.
CONCLUSION
Based on Christianen guidelines, dose constraints to the superior
and middle PCs seem to play a role as dosimetric predictors of
early/late swallowing disturbances.
A common contouring is needed to deﬁne structures that are
involved in the swallowing process to suggest dose–volume con-
straints. In this scenario, prospective trials could be activated to
elucidate the importance of doses to the pharyngeal PCs. Func-
tional and anatomic treatment-related disorders and QoL assess-
ment, including dedicated questionnaires, will be further evaluated
in a prospective way in future analysis.
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